Literature DB >> 11252111

Clostridium difficile--Associated diarrhea: A review.

E Mylonakis1, E T Ryan, S B Calderwood.   

Abstract

Clostridium difficile causes 300 000 to 3 000 000 cases of diarrhea and colitis in the United States every year. Antibiotics most frequently associated with the infection are clindamycin, ampicillin, amoxicillin, and cephalosporins, but all antibiotics may predispose patients to C difficile infection. The clinical presentation varies from asymptomatic colonization to mild diarrhea to severe debilitating disease, with high fever, severe abdominal pain, paralytic ileus, colonic dilation (or megacolon), or even perforation. The most sensitive and specific test available for diagnosis of C difficile infection is a tissue culture assay for the cytotoxicity of toxin B. However, this test takes 1 to 3 days to complete and requires tissue culture facilities. Detection of C difficile toxin by means of enzyme-linked immunoassay is more rapid and inexpensive. A minority of patients may require more than 1 stool assay to detect toxin. Oral metronidazole or oral vancomycin hydrochloride for 10 to 14 days are equally effective at resolving clinical symptoms; oral metronidazole is preferred in most cases because of lowered cost and less selective pressure for vancomycin-resistant organisms. Approximately 15% of patients experience relapse after initial therapy and require retreatment, sometimes with an extended, tapering regimen. Immunity appears to be incomplete and predominantly mediated by serum IgG to toxin A. Measures for preventing the spread of the pathogen, appropriate diagnostic testing, and treatment may avert morbidity and mortality due to C difficile-associated diarrhea.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11252111     DOI: 10.1001/archinte.161.4.525

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  78 in total

1.  Synthesis and antimicrobial evaluation of nitazoxanide-based analogues: identification of selective and broad spectrum activity.

Authors:  T Eric Ballard; Xia Wang; Igor Olekhnovich; Taylor Koerner; Craig Seymour; Joseph Salamoun; Michelle Warthan; Paul S Hoffman; Timothy L Macdonald
Journal:  ChemMedChem       Date:  2010-12-29       Impact factor: 3.466

2.  Mutational analysis of the enzymatic domain of Clostridium difficile toxin B reveals novel inhibitors of the wild-type toxin.

Authors:  Lea M Spyres; Jeremy Daniel; Amy Hensley; Maen Qa'Dan; William Ortiz-Leduc; Jimmy D Ballard
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

3.  Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota.

Authors:  Vincent B Young; Thomas M Schmidt
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

4.  Clostridium difficile colitis in children with cystic fibrosis.

Authors:  Sunny Zaheed Hussain; Cathy Chu; David P Greenberg; David Orenstein; Seema Khan
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

5.  Constipation in Clostridium difficile infection.

Authors:  Hameem I Kawsar; K V Gopal; Jamila Shahnewaz; Hamed A Daw
Journal:  BMJ Case Rep       Date:  2012-07-03

6.  Diagnostic algorithm using a sensitive broth culture method for detection of Clostridium difficile toxin from stool samples.

Authors:  Paul Bayardelle
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

7.  The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease?

Authors:  Justyna Bien; Vindhya Palagani; Przemyslaw Bozko
Journal:  Therap Adv Gastroenterol       Date:  2013-01       Impact factor: 4.409

8.  Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients.

Authors:  R J Friedman-Moraco; A K Mehta; G M Lyon; C S Kraft
Journal:  Am J Transplant       Date:  2014-01-16       Impact factor: 8.086

9.  Clostridium difficile as a cause of healthcare-associated diarrhoea among children in Auckland, New Zealand: clinical and molecular epidemiology.

Authors:  V Sathyendran; G N McAuliffe; T Swager; J T Freeman; S L Taylor; S A Roberts
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-09       Impact factor: 3.267

Review 10.  Pseudomembranous colitis.

Authors:  Priya D Farooq; Nathalie H Urrunaga; Derek M Tang; Erik C von Rosenvinge
Journal:  Dis Mon       Date:  2015-03-11       Impact factor: 3.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.